Health Canada Raises Data Integrity Concerns for TAVNEOS Drug

Health Canada has expressed significant concerns regarding the integrity of data used to authorize TAVNEOS (avacopan), a medication for severe ANCA-associated vasculitis. These issues cast doubt on the drug's effectiveness. As a result, healthcare professionals are advised to avoid initiating new treatments with TAVNEOS and to closely monitor existing patients to determine if continued use is appropriate.